Table 3: Lenalidomide containing regimens in relapsed/refractory indolent and mantle cell lymphoma.

AuthorYearPhaseHistology Age (range)Previous CTCombinationORR (%)CR (%)

Wang et al. [27]2007I/IIMCL1573 (62–84)2 (1–7)RL83*17*
Dutia et al. [28]2009IIIndolent NHL1560 (50–91)4 (1–11)RL83.341
Zaja et al. [29]2011IIMCL3368 (51–80)3 (2–7)LD5224

*: data from patients enrolled in lenalidomide 20 mg/daily arm. No response was obtained for lower dosage.
CT: chemotherapy; ORR: overall response rate; CR: complete response; RL: rituximab and lenalidomide; LD: lenalidomide and dexamethasone.